Can we regrow damaged nerves? A new study identifies the AHR protein as the switch that limits axon regeneration.
Axon is rated a 'Buy' due to strong recurring revenue growth, expanding AI integration, and a dominant market position in security technology. AXON's Q2 2025 revenue rose 33% YoY to $669 million, with ...
Axon has long served law enforcement agencies, but it's expanding into new markets. The company has almost tripled its net income in the last three years. Management estimates its total addressable ...
SCOTTSDALE, Ariz., April 22, 2025 — At its annual user conference today, Axon (Nasdaq: AXON) announced a major expansion of its real-time network and public safety ecosystem, introducing new ...
Hosted on MSN
Why Is Everyone Talking About Axon Enterprise Stock?
In February, Axon Enterprise (NASDAQ: AXON) reported full-year 2024 revenue of $2.1 billion, marking its third consecutive year with over 30% top-line growth. The stock soared over 15% on the earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results